SO-19 Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer

H Taniguchi ,Masato Nakamura ,N Sugimoto ,Kuniaki Shirao ,Shunsō Ishihara ,Jun Watanabe ,M Kotaka ,Hitoshi Ojima ,Yu Sunakawa ,T Kajiwara ,Tetsuji Terazawa ,Takao Tamura ,Taku Nakajima ,Yasutoshi Kuboki ,T Takayama ,Mitsuru Yokota ,Satoru Morita ,T Denda ,T Moriwaki ,Eiji Oki ,Hajime Kawakami ,T Yoshino

doi:10.1016/j.annonc.2022.04.418

SO-19 Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer

H Taniguchi , Masato Nakamura + Show 20 more

Open Access

https://doi.org/10.1016/j.annonc.2022.04.418

Copy DOI

#Treatment For Metastatic Colorectal Cancer #Non-inferiority In Terms + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In primary analysis from the TRUSTY study, trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) failed to show non-inferiority in terms of overall survival (OS) to irinotecan and fluoropyrimidine plus BEV as second-line treatment in patients (pts) with metastatic colorectal cancer (mCRC) who failed first-line chemotherapy with fluoropyrimidine and oxaliplatin plus either BEV or an anti-EGFR antibody (median OS: 14.8 vs. 18.1 months; hazard ratio [HR]: 1.38; 95% CI: 0.99–1.93; p = 0.59 for non-inferiority; Kuboki Y et al., ASCO 2021).

Full Text